High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

Flora Zagouri; Zsuzsanna Bagó-Horváth; Fabian Rössler; Anita Brandstetter; Rupert Bartsch; C.A. Papadimitriou; Constantine Dimitrakakis; Alexandra Tsigginou; Irene Papaspyrou; Aris Giannos; Meletios A Dimopoulos; Martin Filipits

doi:10.1038/bjc.2013.31

Related publications

Article2019

<p>Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study</p>

Despoina Kalapanida, Flora Zagouri, Maria Gazouli, Andriani Tsiakou, Eleni Zografos, Constantine Dimitrakakis, Spyridon S Marinopoulos, Aris Giannos, Theodoros Ν. Sergentanis, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos

Article2015

Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome

Rhiannon K. Beckers, Christina Selinger, Ricardo E. Vilain, Jason Madore, James S. Wilmott, Kate Harvey, Anne Holliday, Caroline Cooper, Elizabeth Robbins, David J. Gillett, Catherine Kennedy, Laurence Gluch, Hugh Carmalt, Cindy Mak, Sanjay Warrier, Harriet E. Gee, Charles Chan, Anna McLean, Emily Walker, Catriona M. McNeil, Jane Beith, Alexander Swarbrick, Richard A Scolyer, Sandra O’Toole

Article2016

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

Giulia Bottai, Carlotta Raschioni, Borbála Székely, Luca Di Tommaso, Attila Marcell Szász, Agnese Losurdo, Balázs Győrffy, Balázs Ács, Rosalba Torrisi, Niki Karachaliou, Tímea Tőkés, Michele Caruso, Janina Kulka, Massimo Roncalli, Armando Santoro, Alberto Mantovani, Rafael Rosell, Jorge S. Reis‐Filho, Libero Santarpia

Article2023

3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer

Javier I. J. Orozco, Sandra Íñiguez-Muñoz, B.C. Valdez, Chuan Wang, Anja Mezger, Eun‐Kyoung Choi, Yan Zhou Tran, Li-Qun Yao, Franziska Bonath, Remi‐André Olsen, Mattias Ormestad, Manel Esteller, Mathieu Lupien, Diego M. Marzese, Pere Llinàs‐Arias, Miquel Ensenyat-Méndez

Article2019

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Begoña Pineda, Ángel Díaz‐Lagares, José Alejandro Pérez Fidalgo, Octavio Burgués, Inés González‐Barrallo, Ana B. Crujeiras, Juan Sandoval, Manel Esteller, Aña Lluch, Pîlar Eroles

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

Abstract

Discussion(0)

Related publications

<p>Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study</p>

Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

Abstract

Discussion(0)

Related publications

&lt;p&gt;Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study&lt;/p&gt;

Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

<p>Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study</p>